Anti-CD20 Monoclonal Antibodies Market Report 2025

The anti-CD20 monoclonal antibodies market size has grown strongly in recent years. It will grow from $8.33 billion in 2024 to $9.0 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to the increasing prevalence of B-cell malignancies, the expanding use of anti-CD20 therapies in treating autoimmune diseases, a rise in FDA and EMA approvals for new anti-CD20 treatments, and the global increase in the geriatric population.

The anti-CD20 monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $12.05 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The anticipated growth in the forecast period can be attributed to a rise in strategic collaborations and licensing agreements, broader application in combination therapies, an increasing number of relapsed or refractory cases, higher healthcare spending and improved access in emerging markets, and the continued development and approval of biosimilars. Key trends expected during this period include innovations in monoclonal antibody engineering, the integration of anti-CD20 antibodies into combination treatment regimens, technology-enabled personalization of cancer therapies, advancements in subcutaneous and long-acting formulations, and progress in bispecific and next-generation antibody development.

The growing prevalence of autoimmune diseases is expected to drive the expansion of the anti-CD20 monoclonal antibodies market. Autoimmune diseases arise when the immune system mistakenly targets the body's own cells, treating them as foreign invaders. The increase in autoimmune conditions is linked to greater exposure to environmental pollutants, which can disrupt immune regulation and provoke attacks on the body's tissues. Anti-CD20 monoclonal antibodies help manage autoimmune diseases by targeting and removing B cells responsible for producing autoantibodies and causing inflammation. These therapies aid in regulating immune activity and alleviating disease symptoms. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that in 2022, approximately 514,000 people (2%) in Australia were living with rheumatoid arthritis, a systemic autoimmune condition, affecting 2.5% of females and 1.6% of males. Thus, the increasing incidence of autoimmune diseases is contributing to the growth of the anti-CD20 monoclonal antibodies market.

Major players in the anti-CD20 monoclonal antibody market are advancing the development of new therapies such as obinutuzumab to address resistant or relapsed B-cell malignancies more effectively. Obinutuzumab is a humanized type II anti-CD20 monoclonal antibody that targets and eliminates CD20-positive B cells involved in certain blood cancers and autoimmune disorders. For instance, in March 2025, Roche, a Switzerland-based biopharmaceutical firm, announced that the US Food and Drug Administration (FDA) had accepted a supplemental Biologics License Application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis. This submission is based on positive results from the Phase III REGENCY study, which demonstrated improved complete renal response (CRR) when the drug was combined with standard therapy compared to standard therapy alone. This positions Gazyva/Gazyvaro as the only anti-CD20 monoclonal antibody to show such benefits in treating lupus nephritis, a serious kidney inflammation caused by lupus.

In August 2023, TG Therapeutics, a US-based manufacturer of anti-CD20 monoclonal antibodies, formed a partnership with Neuraxpharm to expand the global availability of its multiple sclerosis treatment. The collaboration aims to commercialize BRIUMVI, a CD20-targeted monoclonal antibody therapy, in international markets and increase access for patients with relapsing multiple sclerosis outside the United States. Neuraxpharm is a pharmaceutical company headquartered in Germany.

Major players in the anti-cd20 monoclonal antibodies market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Inc., Chugai Pharmaceutical Co. Ltd., Dr. Reddy’s Laboratories, Genmab A/S, Celltrion Inc., Innovent Biologics, Immunomedics, HLL Lifecare Limited, Shanghai Henlius Biotech Inc., TG Therapeutics, Biogen Idec, Aetos Pharma, Nycomed GmbH.

North America was the largest region in the Anti-CD20 monoclonal antibodies market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-CD20 monoclonal antibodies report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the anti-CD20 monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-CD20 monoclonal antibodies market consists of sales of tositumomab, ocrelizumab, ublituximab, and mosunetuzumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The anti-CD20 monoclonal antibodies market research report is one of a series of new reports that provides anti-CD20 monoclonal antibodies market statistics, including the anti-CD20 monoclonal antibodies industry global market size, regional shares, competitors with the anti-CD20 monoclonal antibodies market share, detailed anti-CD20 monoclonal antibodies market segments, market trends, opportunities, and any further data you may need to thrive in the anti-CD20 monoclonal antibodies industry. This anti-CD20 monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Anti-CD20 monoclonal antibodies are targeted immunotherapies designed to bind to the CD20 protein found on the surface of B-cells. These antibodies initiate immune responses such as complement activation and antibody-dependent cell-mediated cytotoxicity, aiding in the destruction of abnormal or malignant B-cells. This focused treatment strategy allows for greater precision and fewer systemic side effects compared to traditional chemotherapy.

The primary types of anti-CD20 monoclonal antibodies include rituximab, obinutuzumab, ofatumumab, and others. Rituximab, which targets CD20, is commonly used in the treatment of B-cell malignancies and autoimmune disorders by depleting abnormal B-cells. It is available in various administration routes, including intravenous and subcutaneous, and is distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online platforms. Rituximab is employed in the treatment of conditions like non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis, multiple sclerosis, pemphigus vulgaris, and others. It is utilized by a range of end-users, including hospitals, surgical and diagnostic centers, maternity facilities, ambulatory care units, academic institutions, and other healthcare settings.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.